...
首页> 外文期刊>Bangladesh Journal of Medical Science >Prompt Response to single injection of Bevacizumab in a case of Fibrinous Central Serous Choroidopathy (CSC).
【24h】

Prompt Response to single injection of Bevacizumab in a case of Fibrinous Central Serous Choroidopathy (CSC).

机译:在纤维性中央性浆液性脉络膜疾病(CSC)的情况下,对单次注射贝伐单抗的反应迅速。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Central Serous Choroidopathy (CSC) is a disease of young and middle aged adults as a localized detachment of the neurosensory retina. Though the cause of CSC remains unknown, it is believed that abnormalities in choroidal circulation make overlying retinal pigment epithelium dysfunctional, resulting in development of a serous retinal detachment. Subretinal fibrin accumulation is rare but vision threatening association of CSC.Methods: A young 31 years female with acute central serous chorioretinopathy received an Intravitreal bevacizumab (1.25 mg/0.05 ml) injection. At baseline and follow-up visits, patients had best corrected visual acuity (BCVA), IOP assessment, dilated fundus examination, fundus photography, fluorescein angiography (FA), and Optical Coherence Topography(OCT) imaging.Results: Patient showed resolution of fibrin, resolution of intraretinal or subretinal fluid promptly, and improvement in visual symptoms and acuity within 1 month. At 6 months patient is maintaining 20/20 vision without any recurrence.Conclusions: Intravitreal bevacizumab injection for acute fibrinous central serous choroidopathy may result in prompt resolution of neurosensory detachment and reduction of angiographic leakage. These short-term results suggest that Intravitreal bevacizumab injection may constitute a promising therapeutic option in fibrinous central serous chorioretinopathy.Bangladesh Journal of Medical Science Vol.16(1) 2017 p.157-160
机译:目的:中枢性浆液性脉络膜病变(CSC)是一种中青年成年人的疾病,是神经感觉视网膜的局部脱离。尽管CSC的病因尚不清楚,但人们认为脉络膜循环异常会使上层视网膜色素上皮功能失调,导致浆液性视网膜脱离。方法:一名31岁的急性中心性浆液性脉络膜视网膜病变的年轻女性接受了玻璃体内贝伐单抗(1.25 mg / 0.05 ml)注射。在基线和随访期间,患者的矫正视力(BCVA),眼压评估,散瞳眼底检查,眼底照相,荧光素血管造影(FA)和光学相干地形图(OCT)成像效果最佳。 ,迅速解决视网膜内或视网膜下积液,并在1个月内改善视觉症状和敏锐度。在6个月时,患者保持20/20视力,无任何复发。结论:玻璃体腔注射贝伐单抗用于急性纤维性中央性浆液性脉络膜病变可迅速缓解神经感觉性脱离并减少血管造影术渗漏。这些短期结果表明玻璃体内贝伐单抗注射可能是纤维化中央性浆液性脉络膜视网膜病变的有前途的治疗选择。孟加拉国医学杂志Vol.16(1)2017 p.157-160

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号